31 Jul 2023
UCB welcomes the epilepsy treatment updates to the WHO Model List of Essential Medicines
Read More27 Jul 2023
Half-Year Report: achieving an inflection point and embarking on a new growth phase
Read MorePagination
Choose a Country
- Global Site – English
- Australia – English
- België – Engels
- Belgique – Anglais
- Brasil – Português
- България – Български
- Canada – English
- Canada – Français
- 中国 – 中文
- Česká Republika – Angličtina
- Danmark – Engelsk
- Deutschland – Deutsch
- France – Français
- España – Español
- Ελλάδα – Ελληνικά
- India – English
- Ireland – English
- Italia – Inglese
- 日本 – 日本語
- 한국 – 한국어
- Luxembourg – Anglais
- Luxemburg – Engels
- Magyarország – Angol
- México & Latinoamérica – Español
- Nederland – Engels
- New Zealand – English
- Norge – Engelsk
- Österreich – Deutsch
- Polska – Polski
- Portugal – Inglês
- România – Engleză
- Россия – Русский
- Slovensko – Anglický
- Suomi – Englanti
- Sverige – Engelska
- Schweiz – Deutsch
- Türkiye – Türkçe
- Україна – Англійська
- United Kingdom – English
- U.S.A. – English
Our Company
Disease Areas
Our Science
Our Products
Newsroom
Investors
Clinical Studies
Advantage Hers
- Advantage Hers English
- Advantage Hers German
- Advantage Hers French
- Advantage Hers Spanish
- Advantage Hers Italian
- Advantage Hers Danish
- Advantage Hers Dutch
- Advantage Hers Polish
- Advantage Hers Greek
- Advantage Hers Finnish
- Advantage Hers Norwegian
- Advantage Hers Romanian
- Advantage Hers Bulgarian
- Advantage Hers Czech
- Advantage Hers Slovak
- Advantage Hers Australia
- Advantage Hers Canada